価格表

在庫・価格 : 2024年05月05日 07時05分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid, Rabbit-Poly
データシート
GTX135357 GNTジーンテックス
GeneTex International Corporation
25 μl ¥24,000
(未発注)
追加

在庫・価格 : 2024年05月05日 07時05分 現在

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid, Rabbit-Poly

  • 商品コード:GTX135357
  • メーカー:GNT
  • 包装:25μl
  • 価格: ¥24,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Corbett KS et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. 2020 07;
Corbett KS et al
2020/01/01
Application: IHC-P PubMed
2 Davide F. Robbiani, et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals, bioRxiv 2020

Application: IHC-Fr PubMed
3 Hoffmann HH et al. TMEM41B Is a Pan-flavivirus Host Factor. Cell 2021 01;184(1):133-148.e20
Hoffmann HH et al
2021/01/01
PubMed
4 Mellott DM et al. A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells. ACS Chem Biol 2021 04;16(4):642-650
Mellott DM et al
2021/01/01
PubMed
5 Rosado-Olivieri E. et al., Rosado-Olivieri E., Cell, 2021

PubMed
6 Li J et al. Microfluidic Magneto Immunosensor for Rapid, High Sensitivity Measurements of SARS-CoV-2 Nucleocapsid Protein in Serum. ACS Sens 2021 03;6(3):1270-1278
Li J et al
2021/01/01
PubMed
7 Meyer M et al. mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge. bioRxiv 2021 Jan;
Meyer M et al
2021/01/01
PubMed
8 Lu-Culligan A et al. SARS-CoV-2 infection in pregnancy is associated with robust inflammatory response at the maternal-fetal interface. medRxiv 2021 Jan;
Lu-Culligan A et al
2021/01/01
PubMed
9 Sukhikh G et al., Sukhikh G, Viruses, 2021

PubMed
10 Mor M et al. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. PLoS Pathog 2021 02;17(2):e1009165
Mor M et al
2021/01/01
PubMed
11 Schmidt F et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. bioRxiv 2020 Jun;
Schmidt F et al
2020/01/01
PubMed
12 Plescia CB et al. SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles. J Biol Chem 2020 Nov;
Plescia CB et al
2020/01/01
PubMed
13 Schneider WM et al. Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. bioRxiv 2020 Oct;
Schneider WM et al
2020/01/01
PubMed
14 Robbiani DF et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020 08;584(7821):437-442
Robbiani DF et al
2020/01/01
PubMed
15 Clausen TM et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell 2020 11;183(4):1043-1057.e15
Clausen TM et al
2020/01/01
PubMed
16 Robbiani DF et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv 2020 May;
Robbiani DF et al
2020/01/01
PubMed
17 Francica JR et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci Transl Med 2021 08;13(607)
Francica JR et al
2021/01/01
PubMed
18 Junqueira C et al. SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. Res Sq 2021 Aug;
Junqueira C et al
2021/01/01
PubMed
19 Verma R et al. RNA-Protein Interaction Analysis of SARS-CoV-2 5" and 3" Untranslated Regions Reveals a Role of Lysosome-Associated Membrane Protein-2a during Viral Infection. mSystems 2021 Aug;6(4):e0064321
Verma R et al
2021/01/01
PubMed
20 Hoffmann HH et al. TMEM41B is a pan-flavivirus host factor. bioRxiv 2020 Oct;
Hoffmann HH et al
2020/01/01
PubMed
21 Mor M et al. Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors. bioRxiv 2020 Oct;
Mor M et al
2020/01/01
PubMed
22 Wang Z et al. Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro. bioRxiv 2020 Sep;
Wang Z et al
2020/01/01
PubMed
23 Eriksen AZ et al. SARS-CoV-2 infects human adult donor eyes and hESC-derived ocular epithelium. Cell Stem Cell 2021 07;28(7):1205-1220.e7
Eriksen AZ et al
2021/01/01
PubMed
24 DiPiazza AT et al. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity 2021 08;54(8):1869-1882.e6
DiPiazza AT et al
2021/01/01
PubMed
25 Li D et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 2021 08;184(16):4203-4219.e32
Li D et al
2021/01/01
PubMed
26 Wang Z et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021 07;595(7867):426-431
Wang Z et al
2021/01/01
PubMed
27 . Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol 2021 05;6(59)

2021/01/01
PubMed
28 Schmidt F et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 2020 11;217(11)
Schmidt F et al
2020/01/01
PubMed
29 Sukhikh G et al. Vertical Transmission of SARS-CoV-2 in Second Trimester Associated with Severe Neonatal Pathology. Viruses 2021 03;13(3)
Sukhikh G et al
2021/01/01
PubMed
30 Saunders KO et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 2021 06;594(7864):553-559
Saunders KO et al
2021/01/01
PubMed
31 Park SH et al. Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity. PLoS Pathog 2021 05;17(5):e1009519
Park SH et al
2021/01/01
PubMed
32 Cantwell AM et al. Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19. J Virol 2021 09;95(20):e0101021
Cantwell AM et al
2021/01/01
PubMed
33 Corbett KS et al. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nat Immunol 2021 10;22(10):1306-1315
Corbett KS et al
2021/01/01
PubMed
34 Corbett KS et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 2021 09;373(6561):eabj0299
Corbett KS et al
2021/01/01
PubMed
35 Wagner TR et al. Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern. EMBO Rep 2022 02;23(2):e53865
Wagner TR et al
2022/01/01
PubMed
36 Yewdell J et al. Cell Surface SARS-CoV-2 Nucleocapsid Protein Modulates Innate and Adaptive Immunity. Res Sq 2021 Dec;
Yewdell J et al
2021/01/01
PubMed
37 Gagne M et al. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell 2022 01;185(1):113-130.e15
Gagne M et al
2022/01/01
PubMed
38 Saiz ML et al. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity. Clin Epigenetics 2021 10;13(1):187
Saiz ML et al
2021/01/01
PubMed
39 Peng YC et al. A Novel Rapid Test to Detect Anti-SARS-CoV-2 N Protein IgG Based on Shear Horizontal Surface Acoustic Wave (SH-SAW). Diagnostics (Basel) 2021 Oct;11(10)
Peng YC et al
2021/01/01
PubMed
40 Kmiec D et al. S-farnesylation is essential for antiviral activity of the long ZAP isoform against RNA viruses with diverse replication strategies. PLoS Pathog 2021 10;17(10):e1009726
Kmiec D et al
2021/01/01
PubMed
41 Carapito R et al. Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Sci Transl Med 2022 Jan;14(628):eabj7521
Carapito R et al
2022/01/01
PubMed
42 Madden PJ et al. An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques. bioRxiv 2022 Mar;
Madden PJ et al
2022/01/01
PubMed
43 Piscotta FJ et al. Metabolites with SARS-CoV-2 Inhibitory Activity Identified from Human Microbiome Commensals. mSphere 2021 Dec;6(6):e0071121
Piscotta FJ et al
2021/01/01
PubMed
44 L坦pez-Mu単oz AD et al. Cell Surface SARS-CoV-2 Nucleocapsid Protein Modulates Innate and Adaptive Immunity. bioRxiv 2021 Dec;
L坦pez-Mu単oz AD et al
2021/01/01
PubMed
45 Li X et al. Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. PLoS Pathog 2021 Sep;17(9):e1009898
Li X et al
2021/01/01
PubMed
46 Knoblach B et al. Peroxisomes exhibit compromised structure and matrix protein content in SARS-CoV-2-infected cells. Mol Biol Cell 2021 07;32(14):1273-1282
Knoblach B et al
2021/01/01
PubMed
47 Lu-Culligan A et al. Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory response at the maternal-fetal interface. Med (N Y) 2021 May;2(5):591-610.e10
Lu-Culligan A et al
2021/01/01
PubMed
48 Rosado-Olivieri EA et al. Self-organized stem cell-derived human lung buds with proximo-distal patterning and novel targets of SARS-CoV-2. bioRxiv 2021 Jan;
Rosado-Olivieri EA et al
2021/01/01
PubMed
49 Hoffmann HH et al. Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. Cell Host Microbe 2021 Feb;29(2):267-280.e5
Hoffmann HH et al
2021/01/01
PubMed
50 Madden P et al. An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques. Res Sq 2022 Apr;
Madden P et al
2022/01/01
PubMed
51 Ariumi Y. Host Cellular RNA Helicases Regulate SARS-CoV-2 Infection. J Virol 2022 Mar;96(6):e0000222
Ariumi Y
2022/01/01
PubMed
52 Vora SM et al. Targeting stem-loop 1 of the SARS-CoV-2 5" UTR to suppress viral translation and Nsp1 evasion. Proc Natl Acad Sci U S A 2022 Mar;119(9)
Vora SM et al
2022/01/01
PubMed
53 Hsu CJ et al. Dynamic Changes of the Blood Chemistry in Syrian Hamsters Post-Acute COVID-19. Microbiol Spectr 2022 Feb;10(1):e0236221
Hsu CJ et al
2022/01/01
PubMed
54 Wang Z et al. Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. bioRxiv 2022 Feb;
Wang Z et al
2022/01/01
PubMed
55 Garcia-Flores V et al. Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2. Nat Commun 2022 Jan;13(1):320
Garcia-Flores V et al
2022/01/01
PubMed
56 Palladino G et al. Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models. Mol Ther Methods Clin Dev 2022 Jun;25:225-235
Palladino G et al
2022/01/01
PubMed
57 Fern叩ndez-Casta単eda A et al. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. bioRxiv 2022 Jan;
Fern叩ndez-Casta単eda A et al
2022/01/01
PubMed
58 Li D et al. Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine. bioRxiv 2022 Feb;
Li D et al
2022/01/01
PubMed
59 Chen PH et al. Saliva-based COVID-19 detection: A rapid antigen test of SARS-CoV-2 nucleocapsid protein using an electrical-double-layer gated field-effect transistor-based biosensing system. Sens Actuators B Chem 2022 Apr;357:131415
Chen PH et al
2022/01/01
PubMed
60 Wei SC et al. An Integrated Platform for Serological Detection and Vaccination of COVID-19. Front Immunol 2021;12:771011
Wei SC et al
2021/01/01
PubMed
61 Bastard P et al. Autoantibodies neutralizing type I IFNs are present in <b>~</b>4% of uninfected individuals over 70 years old and account for <b>~</b>20% of COVID-19 deaths. Sci Immunol 2021 Aug;6(62)
Bastard P et al
2021/01/01
PubMed
62 Vanhulle E et al. SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening. Antiviral Res 2022 Jul;203:105342
Vanhulle E et al
2022/01/01
PubMed
63 Vanhulle E et al. Intracellular flow cytometry complements RT-qPCR detection of circulating SARS-CoV-2 variants of concern. Biotechniques 2022 Jun;72(6):245-254
Vanhulle E et al
2022/01/01
PubMed
64 Chen M et al. Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants. bioRxiv 2022 Apr;
Chen M et al
2022/01/01
PubMed
65 Wang Z et al. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Immunity 2022 Jun;55(6):998-1012.e8
Wang Z et al
2022/01/01
PubMed
66 Gagne M et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 2022 Apr;185(9):1556-1571.e18
Gagne M et al
2022/01/01
PubMed
67 Schneider WM et al. Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks. Cell 2021 Jan;184(1):120-132.e14
Schneider WM et al
2021/01/01
PubMed
68 Wang Z et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med 2021 Jan;13(577)
Wang Z et al
2021/01/01
PubMed
69 Schumann S et al. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19. Int J Mol Sci 2020 Nov;21(22)
Schumann S et al
2020/01/01
PubMed
70 Li X et al. Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models. bioRxiv 2020 Oct;
Li X et al
2020/01/01
PubMed
71 Mellott DM et al. A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells. bioRxiv 2020 Oct;
Mellott DM et al
2020/01/01
PubMed
72 Meewan I et al. Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L. Pharmaceuticals (Basel) 2022 Jun;15(6)
Meewan I et al
2022/01/01
PubMed
73 Setz C et al. Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern. Int J Mol Sci 2022 Jun;23(12)
Setz C et al
2022/01/01
PubMed
74 Fern叩ndez-Casta単eda A et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell 2022 Jul;185(14):2452-2468.e16
Fern叩ndez-Casta単eda A et al
2022/01/01
PubMed
75 Wang Q et al. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Rep 2022 Jun;39(11):110924
Wang Q et al
2022/01/01
PubMed
76 Ueha R et al. Oral SARS-CoV-2 Inoculation Causes Nasal Viral Infection Leading to Olfactory Bulb Infection: An Experimental Study. Front Cell Infect Microbiol 2022;12:924725
Ueha R et al
2022/01/01
PubMed
77 Eriksen AZ et al. Protocols for SARS-CoV-2 infection in primary ocular cells and eye organoids. STAR Protoc 2022 Jun;3(2):101383
Eriksen AZ et al
2022/01/01
PubMed
78 . ;

PubMed
79 Lebedin M et al. Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses. iScience 2024 Mar;27(3):109330
Lebedin M et al
2024/01/01
PubMed
  • No.: 1
  • 文献情報:
    Corbett KS et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. 2020 07;
    Corbett KS et al
    2020/01/01
  • 備考:
    Application: IHC-P
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Davide F. Robbiani, et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals, bioRxiv 2020

  • 備考:
    Application: IHC-Fr
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Hoffmann HH et al. TMEM41B Is a Pan-flavivirus Host Factor. Cell 2021 01;184(1):133-148.e20
    Hoffmann HH et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Mellott DM et al. A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells. ACS Chem Biol 2021 04;16(4):642-650
    Mellott DM et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Rosado-Olivieri E. et al., Rosado-Olivieri E., Cell, 2021

  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Li J et al. Microfluidic Magneto Immunosensor for Rapid, High Sensitivity Measurements of SARS-CoV-2 Nucleocapsid Protein in Serum. ACS Sens 2021 03;6(3):1270-1278
    Li J et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Meyer M et al. mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge. bioRxiv 2021 Jan;
    Meyer M et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Lu-Culligan A et al. SARS-CoV-2 infection in pregnancy is associated with robust inflammatory response at the maternal-fetal interface. medRxiv 2021 Jan;
    Lu-Culligan A et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Sukhikh G et al., Sukhikh G, Viruses, 2021

  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Mor M et al. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. PLoS Pathog 2021 02;17(2):e1009165
    Mor M et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Schmidt F et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. bioRxiv 2020 Jun;
    Schmidt F et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Plescia CB et al. SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles. J Biol Chem 2020 Nov;
    Plescia CB et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Schneider WM et al. Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. bioRxiv 2020 Oct;
    Schneider WM et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Robbiani DF et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020 08;584(7821):437-442
    Robbiani DF et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Clausen TM et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell 2020 11;183(4):1043-1057.e15
    Clausen TM et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Robbiani DF et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv 2020 May;
    Robbiani DF et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Francica JR et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci Transl Med 2021 08;13(607)
    Francica JR et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Junqueira C et al. SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. Res Sq 2021 Aug;
    Junqueira C et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Verma R et al. RNA-Protein Interaction Analysis of SARS-CoV-2 5&quot; and 3&quot; Untranslated Regions Reveals a Role of Lysosome-Associated Membrane Protein-2a during Viral Infection. mSystems 2021 Aug;6(4):e0064321
    Verma R et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Hoffmann HH et al. TMEM41B is a pan-flavivirus host factor. bioRxiv 2020 Oct;
    Hoffmann HH et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Mor M et al. Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors. bioRxiv 2020 Oct;
    Mor M et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Wang Z et al. Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro. bioRxiv 2020 Sep;
    Wang Z et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Eriksen AZ et al. SARS-CoV-2 infects human adult donor eyes and hESC-derived ocular epithelium. Cell Stem Cell 2021 07;28(7):1205-1220.e7
    Eriksen AZ et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    DiPiazza AT et al. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity 2021 08;54(8):1869-1882.e6
    DiPiazza AT et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Li D et al. In&#xA0;vitro and in&#xA0;vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 2021 08;184(16):4203-4219.e32
    Li D et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Wang Z et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 2021 07;595(7867):426-431
    Wang Z et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    . Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol 2021 05;6(59)

    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Schmidt F et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 2020 11;217(11)
    Schmidt F et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Sukhikh G et al. Vertical Transmission of SARS-CoV-2 in Second Trimester Associated with Severe Neonatal Pathology. Viruses 2021 03;13(3)
    Sukhikh G et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Saunders KO et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 2021 06;594(7864):553-559
    Saunders KO et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Park SH et al. Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity. PLoS Pathog 2021 05;17(5):e1009519
    Park SH et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    Cantwell AM et al. Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19. J Virol 2021 09;95(20):e0101021
    Cantwell AM et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    Corbett KS et al. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nat Immunol 2021 10;22(10):1306-1315
    Corbett KS et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 34
  • 文献情報:
    Corbett KS et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 2021 09;373(6561):eabj0299
    Corbett KS et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 35
  • 文献情報:
    Wagner TR et al. Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern. EMBO Rep 2022 02;23(2):e53865
    Wagner TR et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 36
  • 文献情報:
    Yewdell J et al. Cell Surface SARS-CoV-2 Nucleocapsid Protein Modulates Innate and Adaptive Immunity. Res Sq 2021 Dec;
    Yewdell J et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 37
  • 文献情報:
    Gagne M et al. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell 2022 01;185(1):113-130.e15
    Gagne M et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 38
  • 文献情報:
    Saiz ML et al. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity. Clin Epigenetics 2021 10;13(1):187
    Saiz ML et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 39
  • 文献情報:
    Peng YC et al. A Novel Rapid Test to Detect Anti-SARS-CoV-2 N Protein IgG Based on Shear Horizontal Surface Acoustic Wave (SH-SAW). Diagnostics (Basel) 2021 Oct;11(10)
    Peng YC et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 40
  • 文献情報:
    Kmiec D et al. S-farnesylation is essential for antiviral activity of the long ZAP isoform against RNA viruses with diverse replication strategies. PLoS Pathog 2021 10;17(10):e1009726
    Kmiec D et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 41
  • 文献情報:
    Carapito R et al. Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Sci Transl Med 2022 Jan;14(628):eabj7521
    Carapito R et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 42
  • 文献情報:
    Madden PJ et al. An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques. bioRxiv 2022 Mar;
    Madden PJ et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 43
  • 文献情報:
    Piscotta FJ et al. Metabolites with SARS-CoV-2 Inhibitory Activity Identified from Human Microbiome Commensals. mSphere 2021 Dec;6(6):e0071121
    Piscotta FJ et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 44
  • 文献情報:
    L坦pez-Mu単oz AD et al. Cell Surface SARS-CoV-2 Nucleocapsid Protein Modulates Innate and Adaptive Immunity. bioRxiv 2021 Dec;
    L坦pez-Mu単oz AD et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 45
  • 文献情報:
    Li X et al. Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. PLoS Pathog 2021 Sep;17(9):e1009898
    Li X et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 46
  • 文献情報:
    Knoblach B et al. Peroxisomes exhibit compromised structure and matrix protein content in SARS-CoV-2-infected cells. Mol Biol Cell 2021 07;32(14):1273-1282
    Knoblach B et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 47
  • 文献情報:
    Lu-Culligan A et al. Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory response at the maternal-fetal interface. Med (N Y) 2021 May;2(5):591-610.e10
    Lu-Culligan A et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 48
  • 文献情報:
    Rosado-Olivieri EA et al. Self-organized stem cell-derived human lung buds with proximo-distal patterning and novel targets of SARS-CoV-2. bioRxiv 2021 Jan;
    Rosado-Olivieri EA et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 49
  • 文献情報:
    Hoffmann HH et al. Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. Cell Host Microbe 2021 Feb;29(2):267-280.e5
    Hoffmann HH et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 50
  • 文献情報:
    Madden P et al. An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques. Res Sq 2022 Apr;
    Madden P et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 51
  • 文献情報:
    Ariumi Y. Host Cellular RNA Helicases Regulate SARS-CoV-2 Infection. J Virol 2022 Mar;96(6):e0000222
    Ariumi Y
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 52
  • 文献情報:
    Vora SM et al. Targeting stem-loop 1 of the SARS-CoV-2 5&quot; UTR to suppress viral translation and Nsp1 evasion. Proc Natl Acad Sci U S A 2022 Mar;119(9)
    Vora SM et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 53
  • 文献情報:
    Hsu CJ et al. Dynamic Changes of the Blood Chemistry in Syrian Hamsters Post-Acute COVID-19. Microbiol Spectr 2022 Feb;10(1):e0236221
    Hsu CJ et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 54
  • 文献情報:
    Wang Z et al. Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. bioRxiv 2022 Feb;
    Wang Z et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 55
  • 文献情報:
    Garcia-Flores V et al. Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2. Nat Commun 2022 Jan;13(1):320
    Garcia-Flores V et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 56
  • 文献情報:
    Palladino G et al. Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models. Mol Ther Methods Clin Dev 2022 Jun;25:225-235
    Palladino G et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 57
  • 文献情報:
    Fern叩ndez-Casta単eda A et al. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. bioRxiv 2022 Jan;
    Fern叩ndez-Casta単eda A et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 58
  • 文献情報:
    Li D et al. Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine. bioRxiv 2022 Feb;
    Li D et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 59
  • 文献情報:
    Chen PH et al. Saliva-based COVID-19 detection: A rapid antigen test of SARS-CoV-2 nucleocapsid protein using an electrical-double-layer gated field-effect transistor-based biosensing system. Sens Actuators B Chem 2022 Apr;357:131415
    Chen PH et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 60
  • 文献情報:
    Wei SC et al. An Integrated Platform for Serological Detection and Vaccination of COVID-19. Front Immunol 2021;12:771011
    Wei SC et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 61
  • 文献情報:
    Bastard P et al. Autoantibodies neutralizing type I IFNs are present in <b>~</b>4% of uninfected individuals over 70 years old and account for <b>~</b>20% of COVID-19 deaths. Sci Immunol 2021 Aug;6(62)
    Bastard P et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 62
  • 文献情報:
    Vanhulle E et al. SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening. Antiviral Res 2022 Jul;203:105342
    Vanhulle E et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 63
  • 文献情報:
    Vanhulle E et al. Intracellular flow cytometry complements RT-qPCR detection of circulating SARS-CoV-2 variants of concern. Biotechniques 2022 Jun;72(6):245-254
    Vanhulle E et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 64
  • 文献情報:
    Chen M et al. Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants. bioRxiv 2022 Apr;
    Chen M et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 65
  • 文献情報:
    Wang Z et al. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Immunity 2022 Jun;55(6):998-1012.e8
    Wang Z et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 66
  • 文献情報:
    Gagne M et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 2022 Apr;185(9):1556-1571.e18
    Gagne M et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 67
  • 文献情報:
    Schneider WM et al. Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks. Cell 2021 Jan;184(1):120-132.e14
    Schneider WM et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 68
  • 文献情報:
    Wang Z et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med 2021 Jan;13(577)
    Wang Z et al
    2021/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 69
  • 文献情報:
    Schumann S et al. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19. Int J Mol Sci 2020 Nov;21(22)
    Schumann S et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 70
  • 文献情報:
    Li X et al. Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models. bioRxiv 2020 Oct;
    Li X et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 71
  • 文献情報:
    Mellott DM et al. A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells. bioRxiv 2020 Oct;
    Mellott DM et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 72
  • 文献情報:
    Meewan I et al. Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L. Pharmaceuticals (Basel) 2022 Jun;15(6)
    Meewan I et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 73
  • 文献情報:
    Setz C et al. Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern. Int J Mol Sci 2022 Jun;23(12)
    Setz C et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 74
  • 文献情報:
    Fern叩ndez-Casta単eda A et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell 2022 Jul;185(14):2452-2468.e16
    Fern叩ndez-Casta単eda A et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 75
  • 文献情報:
    Wang Q et al. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Rep 2022 Jun;39(11):110924
    Wang Q et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 76
  • 文献情報:
    Ueha R et al. Oral SARS-CoV-2 Inoculation Causes Nasal Viral Infection Leading to Olfactory Bulb Infection: An Experimental Study. Front Cell Infect Microbiol 2022;12:924725
    Ueha R et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 77
  • 文献情報:
    Eriksen AZ et al. Protocols for SARS-CoV-2 infection in primary ocular cells and eye organoids. STAR Protoc 2022 Jun;3(2):101383
    Eriksen AZ et al
    2022/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 78
  • 文献情報:
    . ;

  • 備考:
  • 参照:
    PubMed
  • No.: 79
  • 文献情報:
    Lebedin M et al. Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses. iScience 2024 Mar;27(3):109330
    Lebedin M et al
    2024/01/01
  • 備考:
  • 参照:
    PubMed